Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning

Featuring an interview with Dr Matthew Lunning, including the following topics:

• Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00)
• Overview of the CAR T-cell therapy administration process (4:40)
• Opportunities for referral for CAR T-cell therapy (10:05)
• Selection of a CAR T-cell therapy based on patient characteristics (16:09)
• Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23)
• Safety regulations and mitigation strategies for adverse events (30:36)
• Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16)
• Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09)
• Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09)

CME information and select publications